Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG known ✓ | Q16739 | 3/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 18/20 | 1.00 |
| ▸ | GBA1 | P04062 | 7/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | MGAM | O43451 | 2/20 | 1.00 |
| ▸ | SI | P14410 | 2/20 | 1.00 |
| ▸ | AGL | P35573 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miglustat SCHEMBL7911410 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL19627563 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL19075917 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL7911243 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL7908063 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL23503067 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20577242 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20576705 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20769803 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL719055 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630725-B1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-29 | — | — | EP | claimed |
| US-11713297-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | claimed |
| US-11306058-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-04-19 | — | — | US | claimed |
| US-20220002245-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-01-06 | — | — | US | claimed |
| US-20200140385-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-07 | — | — | US | claimed |
| EP-3630725-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | Idorsia Pharmaceuticals Ltd (CH) | 2020-04-08 | — | — | EP | claimed |
| WO-2018220131-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-12-06 | — | — | WO | claimed |
| EP-1030839-B1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | SEARLE & CO (US) | 2004-02-04 | — | — | EP | claimed |
| EP-4646931-A9 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | Francisco Aragon S.L.U (ES) | 2025-12-24 | — | — | EP | disclosed |
| EP-4646931-A1 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | Francisco Aragon S.L.U (ES) | 2025-11-12 | — | — | EP | disclosed |
| EP-3630725-B1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-29 | — | — | EP | disclosed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| US-12275703-B2 | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same | AMICUS THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-6225325-B1 | ADMINISTERING N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL OR GALACTITOL FOR PROPHYLAXIS, THERAPY, REDUCING, OR REVERSING MULTIDRUG RESISTANCE IN PATIENT UNDERGOING THERAPY WITH CHEMOTHERAPEUTIC AGENT | G.D. SEARLE & COMPANY | 2001-05-01 | — | — | US | disclosed |
| EP-1030839-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-1007043-A1 | METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES | MONSANTO COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999024401-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5798366-A | Method for treatment of CNS-involved lysosomal storage diseases | MONSANTO COMPANY (US) | 1998-08-25 | — | — | US | disclosed |
| WO-1998030219-A1 | METHOD FOR TREATMENT OF CNS-INVOLVED LYSOSOMAL STORAGE DISEASES | MONSANTO COMPANY (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275703-B2 | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same | GANAB, GALK1, GANC | UGCG 29/4885GBA2 180/4885GBA1 98/4885 |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | UGCG 2862/4885GBA2 1400/4885GBA1 940/4885 |
| US-11713297-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | MGAM, UGCG, UGDH | UGCG 2/4885GBA2 99/4885GBA1 53/4885 |
| US-20200140385-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | MGAM, UGCG, UGDH | UGCG 2/4885GBA2 99/4885GBA1 53/4885 |
| US-11306058-B2 | Crystalline form of N-butyldeoxygalactonojirimycin | MGAM, UGCG, UGDH | UGCG 2/4885GBA2 99/4885GBA1 53/4885 |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | UGCG 4592/4885GBA2 1917/4885GBA1 932/4885 |
| US-20220002245-A1 | CRYSTALLINE FORM OF N-BUTYLDEOXYGALACTONOJIRIMYCIN | MGAM, UGCG, UGDH | UGCG 2/4885GBA2 99/4885GBA1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.